Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Lebret

Showing results (141-150 of 147) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 147 results.
The Journal of Clinical Investigation|May 3, 2022
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancerMathieu Rouanne, Julien Adam, Camélia Radulescu, et al.
Clinical Genitourinary Cancer|December 29, 2019
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor GroupMarine Sroussi, Reza Elaidi, Aude Fléchon, et al.
The New England Journal of Medicine|June 2, 2021
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Future Oncology (London, England)|March 15, 2023
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summaryDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 7, 2023
Immune checkpoints are predominantly co-expressed by clonally expanded CD4<sup>+</sup>FoxP3<sup>+</sup> intratumoral T-cells in primary human cancersDelphine Bredel, Edi Tihic, Séverine Mouraud, et al.
European Urology|April 11, 2009
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgeryKarim Bensalah, Allan J Pantuck, Nathalie Rioux-Leclercq, et al.
European Urology|March 8, 2011
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general populationYann Neuzillet, Xavier Tillou, Romain Mathieu, et al.
Pageof 15

Showing results (141-150 of 147) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
The Journal of Clinical Investigation|May 3, 2022
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancerMathieu Rouanne, Julien Adam, Camélia Radulescu, et al.
Clinical Genitourinary Cancer|December 29, 2019
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor GroupMarine Sroussi, Reza Elaidi, Aude Fléchon, et al.
The New England Journal of Medicine|June 2, 2021
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Future Oncology (London, England)|March 15, 2023
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summaryDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 7, 2023
Immune checkpoints are predominantly co-expressed by clonally expanded CD4<sup>+</sup>FoxP3<sup>+</sup> intratumoral T-cells in primary human cancersDelphine Bredel, Edi Tihic, Séverine Mouraud, et al.
European Urology|April 11, 2009
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgeryKarim Bensalah, Allan J Pantuck, Nathalie Rioux-Leclercq, et al.
European Urology|March 8, 2011
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general populationYann Neuzillet, Xavier Tillou, Romain Mathieu, et al.
Pageof 15